A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
Latest Information Update: 20 May 2024
At a glance
- Drugs Linaclotide (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 01 May 2024 Results assessing efficacy and safety of Linaclotide published in the Journal of Pediatric Gastroenterology and Nutrition.
- 09 May 2023 Results of pooled analysis of LIN-MD-64 & LIN-MD-62 assessing safety and tolerability of linaclotide in pediatric patients with functional constipation, presented at the Digestive Disease Week 2023.
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020